Partners

 

MBio partners with industry, government and academia to develop unique, high-value portable technology solutions for diverse applications. MBio’s commercial partnerships are typically confidential, since we develop technologies, in part, as a proprietary product development partner.

 

MBio’s commercial partnerships are matched to partner needs. Typical arrangements often include initial funded feasibility programs followed by more comprehensive product development and supply agreements. In addition to providing instrumentation engineering services around the MBio core LightDeck® technology, the company offers partners extensive assay development expertise. In addition to migrating biological assays to the MBio platform, the MBio team can develop novel assays, unique assay workflows and product stabilization/shelf life strategies. All of this development is supported by a pilot-scale cartridge manufacturing facility with a capacity of fifty thousand cartridges per year to support product development and launch, scalable to millions per year.

Although our commercial partnerships are confidential, below we provide a few examples of our other funded development programs.

UNIVERSITY OF CALIFORNIA, SAN DIEGO

 

Contributing global health and viral disease expertise

 

MBio Diagnostics has developed a longstanding collaboration with a team of world class clinical infectious disease experts at the University of California, San Diego (UCSD). Dr. Robert Schooley is a globally-recognized AIDS and viral disease expert and is Head of the Division of Infectious Diseases, Executive Vice Chairman of the UCSD Department of Medicine and Associate Director of the UCSD Center for AIDS Research. He is a member of the US Department of State’s PEPFAR Scientific Advisory Board and serves as Chairman of the NIH’s Drug Discovery and Resistance Study Section of the National Institutes of Health. He actively advises MBio on test approaches. Dr. Constance Benson is Professor of Medicine and Director of the UCSD Antiviral Research Center (AVRC) and served as Chair of the Executive Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG) from 2002-2010. She is a member of the IAS-USA Panel on HIV Therapeutics. Dr. Benson provides guidance to MBio on clinical testing protocols and trial design.

MBio Diagnostics and the UCSD clinical team have several ongoing research collaborations, including multiple programs funded by the NIH. UCSD and the Antiviral Research Center in San Diego serve as clinical evaluation sites of various MBio assays and devices. MBio Diagnostics also benefits from the global network of infectious disease researchers and sites coordinated by Drs. Schooley and Benson.

Walter Reed Army Institute of Research (WRAIR)

 

MBio has collaborated with the United States Army Medical Research Unit-Kenya (USAMRU-K) on the development of improved malaria diagnostics. It is estimated by the World Health Organization that malaria causes more than 600,000 deaths annually, with 90 percent of those occurring in Africa. Under this program, MBio Diagnostics will develop a low cost, multi-analyte “point-of-care” (POC) diagnostic device for malaria with enhanced sensitivity, quantitation capabilities, and automated data capture and transmission, using the company’s planar waveguide LightDeck® technology. The work is carried out collaboratively with Dr. John Waitumbi of USAMRU-K, which is a “Special Foreign Activity” of the WRAIR headquartered in Nairobi, Kenya. The USAMRU-K unit develops and tests improved means for predicting, detecting, preventing, and treating infectious disease threats important to the U.S. Military as well as conducts surveillance, training, research and response activities related to emerging infectious diseases threats.

MBio – Ireland Partnerships

 

MBio has longstanding collaborations with preeminent laboratories in both Northern Ireland and the Republic of Ireland. The Institute for Global Food Security (IGFS) at Queen’s University, Belfast, Northern Ireland is a leader in toxin detection strategies. IGFS scientists have been working with the MBio system for several years, developing innovative multiplexed immunoassays that deliver extraordinary levels of sensitivity for toxin detection (see the MBio Publications page). MBio’s network also includes the partner institution of Dublin City University. This work continues to appear in high impact scientific journals and the tests are now entering a commercialization phase.